Process Flow Controllers
Selleck Chemical LLC ARS-1323-E1856-100MG
ARS-1323 is the racemic mixture containing ARS-1620 and a potent inhibitor of mutant KRAS G12C It can be used in research for biochemical binding screens as companion imaging drugs (CID) for KRAS G12C
Medchemexpress LLC Ars-1630 | 1698055-86-5 | 430.84 | 10 MG
This compound is a novel inhibitor of mutant K-ras G12C, derived from patent WO 2015054572 A1. It is intended for research use only and not for patient administration.
- Inhibitor of mutant K-ras G12C.
- Utilizes allele-specific covalent targeting of Cys-12.
- Targets an inducible allosteric switch II pocket.
- Requires active cycling between active-GTP and inactive-GDP conformations for targeting.
- Demonstrates feasibility for inhibiting mutant KRAS in laboratory settings.
- High purity (98.10%).
Medchemexpress LLC Ars-1630 | 1698055-86-5 | 430.84 | 50 MG
ARS-1630 is a less active enantiomer of ARS-1620, identified as a novel inhibitor of mutant K-ras G12C. It is intended for research use only.
- Solid appearance
- Color ranges from white to yellow
- Soluble in DMSO at ≥ 100 mg/mL
- Inhibits mutant K-ras G12C by targeting Cys-12
- Requires active cycling of KRASG12C between active-GTP and inactive-GDP conformations
TARGETMOL CHEMICALS INC ARS-853 5MG
Also available in 1mg 10mg 25mg 50mg 100mg 500mg and bulk. Please contact Fisher for quotes. ARS-853 is an inhibitor of K-RASG12C(IC50 : 2.5 μM) a mutant form of K-RAS that accumulates in the active GTP-bound state in certain cancer cellspurity: 98%
Medchemexpress LLC ARS-1630 | 1698055-86-5 | 430.84 | 1 ML
ARS-1630 is a novel inhibitor of mutant K-ras G12C, as described in patent WO 2015054572 A1. It is intended for research use only and is the less active enantiomer of ARS-1620.
- Inhibits mutant K-ras G12C.
- Less active enantiomer of ARS-1620.
- Intended for research use only.
- Purity of 98.1%.
- Provided as a 10 mM solution in 1 mL DMSO.
- Stable for 2 years at -80°C or 1 year at -20°C in solvent; aliquot to prevent freeze-thaw inactivation.
Medchemexpress LLC ARS-853 | 1629268-00-3 | 98.39% | 432.94 | 500 MG
ARS-853 is a cell-active, selective, covalent KRAS G12C inhibitor. It inhibits mutant KRAS-driven signaling by binding to the GDP-bound oncoprotein, thereby preventing its activation. This compound is intended for research use only.
- Cell-active and selective KRAS G12C inhibitor.
- Inhibits mutant KRAS-driven signaling.
- Prevents activation of GDP-bound oncoprotein.
- Reduces GTP-bound KRAS levels by more than 95% at 10 μM in KRASG12C-mutant lung cancer cells.
- Inhibits proliferation, effector signaling, and induces apoptosis in KRASG12C mutant cell lines.
Medchemexpress LLC ARS-853 | 1629268-00-3 | 98.39% | 432.94 | 25 MG
ARS-853 is a cell-active, selective, and covalent KRAS G12C inhibitor with an IC50 of 2.5 μM. It inhibits mutant KRAS-driven signaling by binding to the GDP-bound oncoprotein, thereby preventing its activation.
- Selective KRAS G12C inhibition: designed to bind to KRASG12C with high affinity.
- Potent cellular activity: reduces GTP-bound KRAS levels by over 95% at 10 μM in KRASG12C-mutant lung cancer cells.
- Antiproliferative effects: inhibits proliferation in KRASG12C mutant lung cancer cell lines with an IC50 of 2.5 μM.
- Induces apoptosis in four KRASG12C mutant cell lines.
- Suppresses effector signaling: completely suppresses the effects of exogenous KRASG12C expression on KRAS-GTP levels, KRAS-BRAF interaction, and ERK signaling.
- Intended for research use only.